Mechanisms of colon cancer prevention with and beyond COX-2 inhibition

Current Topics in Medicinal Chemistry

Volumn 5, Issue 5, 2005, Pages 505-516

  Rodriguez Moranta F ^a   Castells, A ^a  

^a UNIVERSITY OF BARCELONA   (Spain)

Author keywords

Apoptosis; Cell proliferation; Chemoprevention; Cyclooxygenase; Epidermal growth factor receptor; Non steroideal antinflammatory drugs; Peroxisome proliferator activated receptor

Indexed keywords

5 (4 FLUOROPHENYL) 1 [(4 METHYLSULFONYL)PHENYL] 3 TRIFLUOROMETHYLPYRAZOLE; ACETYLSALICYLIC ACID; ANGIOSTATIN; BEZAFIBRATE; CALCIUM; CELECOXIB; CYCLOOXYGENASE 1; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITOR; DNA METHYLTRANSFERASE; ENDOSTATIN; FOLIC ACID; FUMAGILLOL CHLOROACETYLCARBAMATE; INTERLEUKIN 12; LIGAND; METALLOPROTEINASE INHIBITOR; METHYLTRANSFERASE INHIBITOR; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; NONSTEROID ANTIINFLAMMATORY AGENT; PELITINIB; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR; PROSTAGLANDIN RECEPTOR; ROFECOXIB; SULINDAC; THALIDOMIDE; THROMBOXANE RECEPTOR BLOCKING AGENT; VITAMIN D;

ANGIOGENESIS; ANTINEOPLASTIC ACTIVITY; APOPTOSIS; CANCER RISK; CANCER SUSCEPTIBILITY; CLINICAL TRIAL; COLORECTAL ADENOMA; COLORECTAL CANCER; COLORECTAL CARCINOMA; DIET THERAPY; DRUG MEGADOSE; ENZYME INHIBITION; FAMILIAL COLON POLYPOSIS; HUMAN; IN VITRO STUDY; IN VIVO STUDY; NONHUMAN; PATHOGENESIS; PROSTAGLANDIN SYNTHESIS; PROTEIN EXPRESSION; REVIEW; RISK REDUCTION;

ANIMALS; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; COLONIC NEOPLASMS; COLORECTAL NEOPLASMS; CYCLOOXYGENASE INHIBITORS; HUMANS;

EID: 22144479056     PISSN: 15680266     EISSN: None     Source Type: Journal    
DOI: 10.2174/1568026054201686     Document Type: Review

References (120)

1. Terdiman, J.P., Conrad, P.G., Sleisenger M.H. Genetic testing in hereditary colorectal cancer, indications and procedures. Am. J. Gastroenterol. 1999, 94(9), 2344-56.
2. Grady, W.M. Genetic testing for high-risk colon cancer patients. Gastroenterol. 2003, 124(6), 1574-94.
3. Kinzler, K.W., Vogelstein, B. Lessons from hereditary colorectal cancer. Cell 1996, 87(2), 159-70.
4. Winawer, S.J., Fletcher, R.H., Miller, L., Godlee, F., Stolar, M.H., Mulrow, C.D., et al. Colorectal cancer screening, clinical guidelines and rationale. Gastroenterol. 1997, 112(2), 594-642.
5. Chung, D.C., Rustgi, A.K. DNA mismatch repair and cancer. Gastroenterol. 1995, 109(5), 1685-99.
6. Chung, D.C. The genetic basis of colorectal cancer, insights into critical pathways of tumorigenesis. Gastroenterol. 2000, 119(3), 854-65.
7. Sporn, M.B., Dunlop, N.M., Newton, D.L., Smith, J.M. Prevention of chemical carcinogenesis by vitamin A and its synthetic analogs (retinoids). Fed. Proc. 1976, 35(6), 1332-8.
8. Kelloff, G.J., Crowell, J.A., Steele, V.E., Lubet, R.A., Boone, C.W., Malone, W.A., et al. Progress in cancer chemoprevention. Ann. NY Acad. Sci. 1999, 889, 1-13.
9. Benner, S.E., Pajak, T.F., Lippman, S.M., Earley, C., Hong, W.K. Prevention of second primary tumors with isotretinoin in patients with squamous cell carcinoma of the head and neck, long-term follow-up. J. Natl. Cancer Inst. 1994, 86(2), 140-1.
10. Baron, J.A., Beach, M., Mandel, J.S. van Stolk RU, Haile RW, Sandler RS., et al. Calcium supplements for the prevention of colorectal adenomas. Calcium Polyp Prevention Study Group. N. Engl. J. Med. 1999, 340(2), 101-7.
11. Alberts, D.S., Martinez, M.E., Roe, D.J., Guillen-Rodriguez, J.M., Marshall, J.R., van Leeuwen, J.B., et al. Lack of effect of a high-fiber cereal supplement on the recurrence of colorectal adenomas. Phoenix Colon Cancer Prevention Physicians' Network. N. Engl. J. Med. 2000, 342(16), 1156-62.
12. Schatzkin, A., Lanza, E., Corle, D., Lance, P., Iber, F., Caan, B., et al. Lack of effect of a low-fat, high-fiber diet on the recurrence of colorectal adenomas. Polyp Prevention Trial Study Group. N. Engl. J. Med. 2000, 342(16), 1149-55.
13. Dubois, R.N., Abramson, S.B., Crofford, L., Gupta, R.A., Simon, L.S., Van De Putte, L.B., et al. Cyclooxygenase in biology and disease. FASEB J 1998, 12(12), 1063-73.
14. Gasparini, G., Longo, R., Sarmiento, R., Morabito, A. Inhibitors of cyclo-oxygenase 2, a new class of anticancer agents? Lancet Oncol. 2003, 4(10), 605-15.
15. Evans, J.H., Spencer, D.M., Zweifach, A., Leslie, C.C. Intracellular calcium signals regulating cytosolic phospholipase A2 translocation to internal membranes. J. Biol. Chem. 2001, 276(32), 30150-60.
16. Herschman, H.R. Prostaglandin synthase 2. Biochim. Biophys. Acta. 1996, 1299(1), 125-40.
17. Gupta, R.A., Dubois, R.N. Colorectal cancer prevention and treatment by inhibition of cyclooxygenase-2. Nat. Rev. Cancer 2001, 1(1), 11-21.
18. Sugimoto, Y., Narumiya, S., Ichikawa, A. Distribution and function of prostanoid receptors, studies from knockout mice. Prog. Lipid Res. 2000, 39(4), 289-314.
19. Bhattacharya, M., Peri, K.G., Almazan, G., Ribeiro-da-Silva, A., Shichi, H., Durocher, Y., et al. Nuclear localization of prostaglandin E2 receptors. Proc. Natl. Acad. Sci. USA 1998, 95(26), 15792-7.
20. Sheng, H., Shao, J., Morrow, J.D., Beauchamp, R.D., DuBois, R.N. Modulation of apoptosis and Bcl-2 expression by prostaglandin E2 in human colon cancer cells. Cancer Res. 1998, 58(2), 362-6.
21. Adam, L., Mazumdar, A., Sharma, T., Jones, T.R., Kumar, R. A three-dimensional and temporo-spatial model to study invasiveness of cancer cells by heregulin and prostaglandin E2. Cancer Res. 2001, 61(1), 81-7.
22. Watanabe, K., Kawamori, T., Nakatsugi, S., Ohta, T., Ohuchida, S., Yamamoto, H., et al. Role of the prostaglandin E receptor subtype EP1 in colon carcinogenesis. Inhibitory effect of a prostaglandin E receptor subtype EP(1) selective antagonist, ONO-8713, on development of azoxymethane-induced aberrant crypt foci in mice. Cancer Res. 1999, 59(20), 5093-6.
23. Watanabe, K., Kawamori, T., Nakatsugi, S., Ohta, T., Ohuchida, S., Yamamoto, H., et al. Inhibitory effect of a prostaglandin E receptor subtype EP(1) selective antagonist, ONO-8713, on development of azoxymethane-induced aberrant crypt foci in mice. Cancer Lett. 2000, 156(1), 57-61.
24. Bennett, A., Tacca, M.D., Stamford, I.F., Zebro, T. Prostaglandins from tumours of human large bowel. Br. J. Cancer 1977, 35(6), 881-4.
25. Chaimoff, C., Malachi, T, Halbrecht I. Prostaglandin E2 and cyclic nucleotides in plasma and urine of colonic cancer patients. J. Cancer Res. Clin. Oncol. 1985, 110(2), 153-6.
26. Rigas, B., Goldman, I.S., Levine, L. Altered eicosanoid levels in human colon cancer. J. Lab. Clin. Med. 1993, 122(5), 518-23.
27. Hendrickse, C.W., Kelly, R.W., Radley, S., Donovan, I.A, Keighley, M.R., Neoptolemos, J.P. Lipid peroxidation and prostaglandins in colorectal cancer. Br. J. Surg. 1994, 81(8), 1219-23.
28. Eberhart, C.E., Coffey, R.J., Radhika, A., Giardiello, F.M., Ferrenbach, S., DuBois, R.N. Up-regulation of cyclooxygenase 2 gene expression in human colorectal adenomas and adenocarcinomas. Gastroenterol. 1994, 107(4), 1183-8.
29. Williams, C.S., Luongo, C., Radhika, A., Zhang, T., Lamps, L.W., Nanney, L.B., et al. Elevated cyclooxygenase-2 levels in Min mouse adenomas. Gastroenterol. 1996, 111(4), 1134-40.
30. DuBois, R.N., Radhika, A., Reddy, B.S., Entingh, A.J. Increased cyclooxygenase-2 levels in carcinogen-induced rat colonic tumors. Gastroenterol. 1996, 110(4), 1259-62.
31. Oshima, M., Dinchuk, J.E., Kargman, S.L., Oshima, H., Hancock, B., Kwong, E., et al. Suppression of intestinal polyposis in Apc delta716 knockout mice by inhibition of cyclooxygenase 2 (COX-2). Cell 1996, 87(5), 803-9.
32. Shao, J., Sheng, H., Aramandla, R., Pereira, M.A., Lubet, R.A., Hawk, E., et al. Coordinate regulation of cyclooxygenase-2 and TGF-beta1 in replication error-positive colon cancer and azoxymethane-induced rat colonic tumors. Carcinogenesis 1999, 20(2), 185-91.
33. Kutchera, W., Jones, D.A., Matsunami, N., Groden, J., McIntyre, T.M., Zimmerman, G.A., et al. Prostaglandin H synthase 2 is expressed abnormally in human colon cancer, evidence for a transcriptional effect. Proc. Natl. Acad. Sci. USA 1996, 93(10), 4816-20.
34. Chapple, K.S., Cartwright, E.J., Hawcroft, G., Tisbury, A., Bonifer, C., Scott, N., et al. Localization of cyclooxygenase-2 in human sporadic colorectal adenomas. Am. J. Pathol. 2000, 156(2), 545-53.
35. Masferrer, J.L., Leahy, K.M., Koki, A.T., Zweifel, B.S., Settle, S.L., Woerner, B.M., et al. Antiangiogenic and antitumor activities of cyclooxygenase-2 inhibitors. Cancer Res. 2000, 60(5), 1306-11.
36. Shattuck-Brandt, R.L., Varilek, G.W., Radhika, A., Yang, F., Washington, M.K., DuBois, R.N. Cyclooxygenase 2 expression is increased in the stroma of colon carcinomas from IL-10(-/-) mice. Gastroenterol. 2000, 118(2), 337-45.
37. Bamba, H., Ota, S., Kato, A., Adachi, A., Itoyama, S., Matsuzaki, F. High expression of cyclooxygenase-2 in macrophages of human colonic adenoma. Int. J. Cancer 1999, 83(4), 470-5.
38. Sano, H., Kawahito, Y., Wilder, R.L., Hashiramoto, A., Mukai, S., Asai, K., et al. Expression of cyclooxygenase-1 and -2 in human colorectal cancer. Cancer Res. 1995, 55(17), 3785-9.
39. Hao, X., Bishop, A.E., Wallace, M., Wang, H., Willcocks, T.C., Maclouf, J., et al. Early expression of cyclo-oxygenase-2 during sporadic colorectal carcinogenesis. J. Pathol. 1999, 187(3), 295-301.
40. Fujita, T., Matsui, M., Takaku, K., Uetake, H., Ichikawa, W., Taketo, M.M., et al. Size- and invasion-dependent increase in cyclooxygenase 2 levels in human colorectal carcinomas. Cancer Res. 1998, 58(21), 4823-6.
41. Chen, W.S., Wei, S.J., Liu, J.M., Hsiao, M., Kou-Lin, J., Yang, W.K. Tumor invasiveness and liver metastasis of colon cancer cells correlated with cyclooxygenase-2 (COX-2) expression and inhibited by a COX-2-selective inhibitor, etodolac. Int. J. Cancer 2001, 91(6), 894-9.
42. Zhang, H., Sun, X.F. Overexpression of cyclooxygenase-2 correlates with advanced stages of colorectal cancer. Am. J. Gastroenterol. 2002, 97(4), 1037-41.
43. Tsujii, M., Kawano, S., DuBois, R.N. Cyclooxygenase-2 expression in human colon cancer cells increases metastatic potential. Proc. Natl. Acad. Sci. USA 1997, 94(7), 3336-40.
44. Tomozawa, S., Tsuno, N.H., Sunami, E., Hatano, K., Kitayama, J., Osada, T., et al. Cyclooxygenase-2 overexpression correlates with tumour recurrence, especially haematogenous metastasis, of colorectal cancer. Br. J. Cancer 2000, 83(3), 324-8.
45. Sheehan, K.M., Sheahan, K., O'Donoghue, D.P., MacSweeney, F., Conroy, R.M., Fitzgerald, D.J., et al. The relationship between cyclooxygenase-2 expression and colorectal cancer. JAMA 1999, 282(13), 1254-7.
46. Masunaga, R., Kohno, H., Dhar, D.K., Ohno, S., Shibakita, M., Kinugasa, S., et al. Cyclooxygcnase-2 expression correlates with tumor neovascularization and prognosis in human colorectal carcinoma patients. Clin. Cancer Res. 2000, 6(10), 4064-8.
47. Garcia-Rodriguez, L.A., Huerta-Alvarez C. Reduced risk of colorectal cancer among long-term users of aspirin and nonaspirin nonsteroidal antiinflammatory drugs. Epidemiol. 2001, 12(1), 88-93.
48. Steinbach, G., Lynch, P.M., Phillips, R.K., Wallace, M.H., Hawk, E., Gordon G.B., et al. The effect of celecoxib, a cyclooxygenase-2 inhibitor, in familial adenomatous polyposis. N. Engl. J. Med. 2000, 342(26), 1946-52.
49. Baron, J.A., Cole, B.F., Sandler, R.S., Haile, R.W., Ahnen, D., Bresalier, R., et al. A randomized trial of aspirin to prevent colorectal adenomas. N. Engl. J. Med. 2003, 348(10), 891-9.
50. Sandler, R.S., Halabi, S., Baron, J.A., Budinger, S., Paskett, E., Keresztes, R., et al. A randomized trial of aspirin to prevent colorectal adenomas in patients with previous colorectal cancer. N. Engl. J. Med. 2003, 348(10), 883-90.
51. FitzGerald, G.A., Patrono, C. The coxibs, selective inhibitors of cyclooxygenase-2. N. Engl. J. Med. 2001, 345(6), 433-42.
52. Janne, P.A., Mayer, R.J. Chemoprevention of colorectal cancer. N. Engl. J. Med. 2000, 342(26), 1960-8.
53. Folkman, J., Watson, K., Ingber, D., Hanahan, D. Induction of angiogenesis during the transition from hyperplasia to neoplasia. Nat. 1989, 339(6219), 58-61.
54. Folkman, J. Tumor angiogenesis and tissue factor. Nat. Med. 1996, 2(2), 167-8.
55. Blood, C.H., Zetter, B.R. Tumor interactions with the vasculature, angiogenesis and tumor metastasis. Biochim. Biophys. Acta. 1990, 1032(1), 89-118.
56. Veikkola, T., Alitalo, K. VEGFs, receptors and angiogenesis. Semin. Cancer Biol. 1999, 9(3), 211-20.
57. Ferrara, N., Davis-Smyth, T. The biology of vascular endothelial growth factor. Endocr. Rev. 1997, 18(1), 4-25.
58. Senger, D.R., Van de Water, L., Brown, L.F., Nagy, J.A., Yeo, K.T., Yeo, T.K., et al. Vascular permeability factor (VPF, VEGF) in tumor biology. Canc. Metastasis Rev. 1993, 12(3-4), 303-24.
59. Veikkola, T., Karkkainen, M., Claesson-Welsh, L., Alitalo, K. Regulation of angiogenesis via vascular endothelial growth factor receptors. Cancer Res. 2000, 60(2), 203-12.
60. Shing, Y., Folkman, J., Sullivan, R., Butterfield, C., Murray, J., Klagsbrun, M. Heparin affinity, purification of a tumor-derived capillary endothelial cell growth factor. Science 1984, 223(4642), 1296-9.
61. Rifkin, D.B., Moscatelli, D. Recent developments in the cell biology of basic fibroblast growth factor. J. Cell Biol. 1989, 109(1), 1-6.
62. Rubin, J.S., Chan, A,M., Bottaro, D.P., Burgess, W.H., Taylor, W.G., Cech, A.C., et al. A broad-spectrum human lung fibroblast-derived mitogen is a variant of hepatocyte growth factor. Proc. Natl. Acad. Sci. USA 1991, 88(2), 415-9.
63. Di Renzo, M.F., Olivero, M., Giacomini, A., Porte, H., Chastre, E., Mirossay, L., et al. Overexpression and amplification of the met/HGF receptor gene during the progression of colorectal cancer. Clin. Cancer Res. 1995, 1 (2), 147-54.
64. Harris, A.L. Antiangiogenesis for cancer therapy. Lancet. 1997, 349(Suppl 2), SII13-5.
65. Rak, J., Filmus, J., Finkenzeller, G., Grugel, S., Marme, D., Kerbel, R.S. Oncogenes as inducers of tumor angiogenesis. Canc. Metastasis Rev. 1995, 14(4), 263-77.
66. Van Meir, E.G., Polverini, P.J., Chazin, V.R., Su, Huang, H.J., de Tribolet, N., Cavenee, W.K. Release of an inhibitor of angiogenesis upon induction of wild type p53 expression in glioblastoma cells. Nat. Genet. 1994, 8(2), 171-6.
67. Tsujii, M., Kawano, S., Tsuji, S., Sawaoka, H., Hori, M., DuBois, R.N. Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 1998, 93(5), 705-16.
68. Cianchi, F, Cortesini, C., Bechi, P., Fantappie, O., Messerini, L., Vannacci, A., et al. Up-regulation of cyclooxygenase 2 gene expression correlates with tumor angiogenesis in human colorectal cancer. Gastroenterol. 2001, 121(6), 1339-47.
69. Carmeliet, P., Jain, R.K. Angiogenesis in cancer and other diseases. Nat. 2000, 407(6801), 249-57.
70. Daniel, T.O., Liu, H., Morrow, J.D., Crews, B.C., Marnett, L.J. Thromboxane A2 is a mediator of cyclooxygenase-2-dependent endothelial migration and angiogenesis. Cancer Res. 1999, 59(18), 4574-7.
71. Seno, H., Oshima, M., Ishikawa, T.O., Oshima, H., Takaku, K., Chiba, T., et al. Cyclooxygenase 2- and prostaglandin E(2) receptor EP(2)-dependent angiogenesis in Apc(Delta716) mouse intestinal polyps. Cancer Res. 2002, 62(2), 506-11.
72. Hengartner, M.O. The biochemistry of apoptosis. Nature 2000, 407(6805), 770-6.
73. Green, D.R., Evan, G.I. A matter of life and death. Cancer Cell 2002, 1(1), 19-30.
74. Chan, T.A., Morin, P.J., Vogelstein, B., Kinzler, K.W. Mechanisms underlying nonsteroidal antiinflammatory drug-mediated apoptosis. Proc. Natl. Acad. Sci. USA 1998, 95(2), 681-6.
75. Tegeder, I., Pfeilschifter, J., Geisslinger, G. Cyclooxygenase-independent actions of cyclooxygenase inhibitors. FASEB J. 2001, 15(12), 2057-72.
76. Richter, M., Weiss, M., Weinberger, I., Furstenberger, G., Marian, B. Growth inhibition and induction of apoptosis in colorectal tumor cells by cyclooxygenase inhibitors. Carcinogenesis 2001, 22(1), 17-25.
77. Poligone, B., Baldwin, A.S. Positive and negative regulation of NF-kappaB, by COX-2, roles of different prostaglandins. J. Biol. Chem. 2001, 276(42), 38658-64.
78. Zhang, Z., DuBois, R.N. Detection of differentially expressed genes in human colon carcinoma cells treated with a selective COX-2 inhibitor. Oncogene 2001, 20(33), 4450-6.
79. Yamazaki, R., Kusunoki, N., Matsuzaki, T., Hashimoto, S., Kawai, S. Selective cyclooxygenase-2 inhibitors show a differential ability to inhibit proliferation and induce apoptosis of colon adenocarcinoma cells. FEBS Lett. 2002, 531(2), 278-84.
80. Marx, J. Cancer research. Anti-inflammatories inhibit cancer growth - but how?. Science 2001, 291(5504), 581-2.
81. Sawaoka, H., Tsuji, S., Tsujii, M., Gunawan, E.S., Sasaki, Y., Kawano, S., et al. Cyclooxygenase inhibitors suppress angiogenesis and reduce tumor growth in vivo. Lab. Invest. 1999, 79(12), 1469-77.
82. Williams, C.S., Watson, A.J., Sheng, H., Helou, R., Shao, J., DuBois, R.N. Celecoxib prevents tumor growth in vivo without toxicity to normal gut, lack of correlation between in vitro and in vivo models. Cancer Res. 2000, 60(21),6045-51.
83. Leahy, K.M., Ornberg, R.L., Wang, Y., Zweifel, B.S., Koki, A.T, Masferrer JL. Cyclooxygenase-2 inhibition by celecoxib reduces proliferation and induces apoptosis in angiogenic endothelial cells in vivo. Cancer Res. 2002, 62(3), 625-31.
84. Mauch C, Krieg T, Bauer EA. Role of the extracellular matrix in the degradation of connective tissue. Arch. Dermatol. Res. 1994, 287(1), 107-14.
85. Nelson, A.R., Fingleton, B., Rothenberg, M.L., Matrisian, L.M. Matrix metalloproteinases, biologic activity and clinical implications. J. Clin. Oncol., 2000, 18(5), 1135-49.
86. Attiga, F.A., Fernandez, P.M., Weeraratna, A.T., Manyak, M.J., Patierno, S.R. Inhibitors of prostaglandin synthesis inhibit human prostate tumor cell invasiveness and reduce the release of matrix metalloproteinases. Cancer Res. 2000, 60(16), 4629-37.
87. Jiang, M.C., Liao, C.F., Lee, P.H. Aspirin inhibits matrix metalloproteinase-2 activity, increases E-cadherin production, and inhibits in vitro invasion of tumor cells. Biochem. Biophys. Res. Commun. 2001, 282(3), 671-7.
88. Pan, M.R., Chuang, L.Y., Hung, W.C. Non-steroidal antiinflammatory drugs inhibit matrix metalloproteinase-2 expression via repression of transcription in lung cancer cells. FEBS Lett. 2001, 508(3), 365-8.
89. Jackson, L., Wahli, W., Michalik, L., Watson, S.A., Morris, T., Anderton, K., et al. Potential role for peroxisome proliferator activated receptor (PPAR) in preventing colon cancer. Gut 2003, 52(9), 1317-22.
90. Meade, E.A., McIntyre, T.M., Zimmerman, G.A., Prescott, S.M. Peroxisome proliferators enhance cyclooxygenase-2 expression in epithelial cells. J. Biol. Chem. 1999, 274(12), 8328-34.
91. Staels, B., Koenig, W., Habib, A., Merval, R., Lebret, M., Torra, I.P., et al. Activation of human aortic smooth-muscle cells is inhibited by PPARalpha but not by PPARgamma activators. Nature 1998, 393(6687), 790-3.
92. Lehmann, J.M., Lenhard, J.M., Oliver, B.B., Ringold, G.M., Kliewer, S.A. Peroxisome proliferator-activated receptors alpha and gamma are activated by indomethacin and other non-steroidal anti-inflammatory drugs. J. Biol. Chem. 1997, 272(6), 3406-10.
93. He, T.C., Chan, T.A., Vogelstein, B., Kinzler, K.W. PPARdelta is an APC-regulated target of nonsteroidal anti-inflammatory drugs. Cell 1999, 99(3), 335-45.
94. Lefebvre, A.M., Chen, I., Desreumaux, P., Najib, J., Fruchart, J.C, Geboes, K., et al. Activation of the peroxisome proliferator-activated receptor gamma promotes the development of colon tumors in C57BL/6J-APCMin/+ mice. Nat. Med. 1998, 4(9), 1053-7.
95. Saez, E., Tontonoz, P., Nelson, M.C., Alvarez, J.G., Ming, U.T, Baird, S.M., et al. Activators of the nuclear receptor PPARgamma enhance colon polyp formation. Nat. Med. 1998, 4(9), 1058-61.
96. Suzuki, I., Iigo, M., Ishikawa, C., Kuhara, T., Asamoto, M., Kunimoto, T., et al. Inhibitory effects of oleic and docosahexaenoic acids on lung metastasis by colon-carcinoma-26 cells are associated with reduced matrix metalloproteinase-2 and -9 activities. Int. J. Cancer 1997, 73(4), 607-12.
97. Beck, S.A., Smith, K.L., Tisdale, M.J. Anticachectic and antitumor effect of eicosapentaenoic acid and its effect on protein turnover. Cancer Res. 1991, 51(22), 6089-93.
98. Anti, M., Marra, G., Armelao, F., Bartoli, G.M., Ficarelli, R., Percesepe, A., et al. Effect of omega-3 fatty acids on rectal mucosal cell proliferation in subjects at risk for colon cancer. Gastroenterol. 1992, 103(3), 883-91.
99. Tanaka, T., Kohno, H., Yoshitani, S., Takashima, S., Okumura, A., Murakami, A., et al. Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res. 2001, 61(6), 2424-8.
100. Kapitanovic, S., Radosevic, S., Kapitanovic, M., Andelinovic, S., Ferencic, Z., Tavassoli, M., et al. The expression of p185(HER-2/neu) correlates with the stage of disease and survival in colorectal cancer. Gastroenterol. 1997, 112(4), 1103-13.
101. Saeki, T., Stromberg, K., Qi, C.F, Gullick, W.J., Tahara, E., Normanno, N., et al. Differential immunohistochemical detection of amphiregulin and cripto in human normal colon and colorectal tumors. Cancer Res. 1992, 52(12), 3467-73.
102. Kirschbaum, M.H., Yarden, Y. The ErbB/HER family of receptor tyrosine kinases, A potential target for chemoprevention of epithelial neoplasms. J. Cell Biochem. Suppl. 2000, 34, 52-60.
103. Pegram, M.D., Lipton, A., Hayes, D.F., Weber, B.L., Baselga, J.M., Tripathy, D., et al. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J. Clin. Oncol. 1998, 16(8), 2659-71.
104. Torrance, C.J., Jackson, P.E., Montgomery, E., Kinzler, K.W., Vogelstein, B, Wissner, A., et al. Combinatorial chemoprevention of intestinal neoplasia. Nat. Med. 2000, 6(9), 1024-8.
105. Gupta, R.A., DuBois, R.N. Combinations for cancer prevention. Nat. Med. 2000, 6(9), 974-5.
106. Kallay, E., Kifor, O., Chattopadhyay, N., Brown, E.M., Bischof, M.G., Peterlik, M., et al. Calcium-dependent c-myc proto-oncogene expression and proliferation of Caco-2 cells, a role for a luminal extracellular calcium-sensing receptor. Biochem. Biophys. Res. Commun. 1997, 232(1), 80-3.
107. Black, J.D. Protein kinase C isozymes in colon carcinogenesis, guilt by omission. Gastroenterol. 2001, 120(7), 1868-72.
108. Sheinin, Y., Kallay, E., Wrba, F., Kriwanek, S., Peterlik, M., Cross, H.S. Immunocytochemical localization of the extracellular calcium-sensing receptor in normal and malignant human large intestinal mucosa. J. Histochem. Cytochem. 2000, 48(5), 595-602.
109. Chakrabarty, S., Radjendirane, V., Appelman, H., Varani, J. Extracellular calcium and calcium sensing receptor function in human colon carcinomas, promotion of E-cadherin expression and suppression of beta-catenin/TCF activation. Cancer Res. 2003, 63(1), 67-71.
110. Kallay, E., Bajna, E., Wrba, F., Kriwanek, S., Peterlik, M., Cross, H.S. Dietary calcium and growth modulation of human colon cancer cells, role of the extracellular calcium-sensing receptor. Cancer Detect Prev. 2000, 24(2), 127-36.
111. Gelebart, P., Kovacs, T., Brouland, J.P., van Gorp, R., Grossmann, J., Rivard, N., et al. Expression of endomembrane calcium pumps in colon and gastric cancer cells. Induction of SERCA3 expression during differentiation. J. Biol. Chem. 2002, 277(29), 26310-20.
112. Cross, H.S., Bareis, P., Hofer, H., Bischof, M.G., Bajna, E, Kriwanek, S., et al. 25-Hydroxyvitamin D(3)-1alpha-hydroxylase and vitamin D receptor gene expression in human colonic mucosa is elevated during early cancerogenesis. Steroids 2001, 66(3-5), 287-92.
113. Vandewalle, B., Wattez, N., Lefebvre, J. Effects of vitamin D3 derivatives on growth, differentiation and apoptosis in tumoral colonic HT 29 cells, possible implication of intracellular calcium. Cancer Lett. 1995, 97(1), 99-106.
114. Giovannucci, E. Epidemiologic studies of folate and colorectal neoplasia, a review. J. Nutr. 2002, 132(8 Suppl.), 2350S-2355S.
115. Pufulete, M., Al-Ghnaniem, R., Leather, A.J, Appleby, P., Gout, S., Terry, C., et al. Folate status, genomic DNA hypomethylation, and risk of colorectal adenoma and cancer, a case control study. Gastroenterol. 2003, 124(5), 1240-8.
116. Song, J., Medline, A., Mason, J.B., Gallinger, S., Kim, Y.I. Effects of dietary folate on intestinal tumorigenesis in the apcMin mouse. Cancer Res. 2000, 60(19), 5434-40.
117. Song, J., Sohn, K.J., Medline, A., Ash, C., Gallinger, S., Kim, Y.I. Chemopreventive effects of dietary folate on intestinal polyps in Apc+/-Msh2-/- mice. Cancer Res. 2000, 60(12), 3191-9.
118. Esteller, M., Corn, P.G., Baylin, S.B., Herman, J.G. A gene hypermethylation profile of human cancer. Cancer Res. 2001, 61(8), 3225-9.
119. Jones, P.A., Baylin, S.B. The fundamental role of epigenetic events in cancer. Nat. Rev. Genet. 2002, 3(6), 415-28.
120. Kopelovich, L., Crowell, J.A., Fay, J.R. The epigenome as a target for cancer chemoprevention. J. Natl. Cancer Inst. 2003, 95(23), 1747-57.